Novartis building

Novartis to Launch Phase 3 Hydroxychloroquine Trial for COVID-19

April 21, 2020

Novartis said it will begin enrollment in the next few weeks for a phase 3 clinical trial to evaluate hydroxychloroquine for treatment of hospitalized COVID-19 patients. The trial will include more than 440 participants at more than a dozen U.S. sites.

If the product is approved for COVID-19, Novartis will release its intellectual property relating to hydroxychloroquine for use by other drugmakers.

The company also committed to donating 130 million hydroxychloroquine tablets for global clinical research efforts.

View today's stories